Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 68

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 68
---
 our stockholders and, we will consider the outcome of the vote when determining the frequency of future advisory votes to approve executive compensation. The outcome of the vote, however, will not be construed as overruling any prior decision by the Company, the Compensation Committee or the Board.

Vote Required

In voting on Proposal 4, you can choose whether the advisory vote on executive compensation should be conducted every one year, every two years or every three years. You may also abstain from voting on this item. The approval requirement for this proposal is a plurality of the votes cast. The frequency option receiving the most votes cast by stockholders will be the frequency that is recommended by stockholders. Abstentions and broker non-votes will have no effect on the outcome of the proposal.

Recommendation of the Board

<div align='center'>THE BOARD UNANIMOUSLY RECOMMENDS THAT FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION BE HELD EVERY YEAR.

50

PROPOSAL 5:

APPROVE THE REGENXBIO INC. 2025 EQUITY INCENTIVE PLAN</div>

We are asking our stockholders to approve the REGENXBIO INC. 2025 Equity Incentive Plan (the “2025 Plan”). The Board of Directors (the “Board”) intends to approve the 2025 Plan on May 30, 2025, subject to receipt of stockholder approval, and if approved by the stockholders, the 2025 Plan will become effective on May 30, 2025.

We currently maintain the REGENXBIO Inc. 2015 Equity Incentive Plan (the “2015 Plan”), which is scheduled to expire on June 17, 2025. As of April 1, 2025, a total of 14,138,418 shares of common stock were subject to outstanding awards under the 2015 Plan, 20,602 shares of common stock were subject to outstanding awards under our other equity plans (our ESPP and our 2014 Stock Plan, which was the predecessor to the 2015 Plan), and an additional 857,842 shares of our common stock were available for the issuance of new awards under the 2015 Plan. The 2025 Plan is intended to be the successor to the 2015 Plan.

If stockholders do not approve the 2025 Plan, we will no longer have the ability to grant equity compensation to employees and directors after June 17,